Glen Rock, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery.
IU researchers developing noninvasive brain stimulation technique to treat neurological disorders
Indiana University School of Medicine researchers are developing a new, noninvasive brain stimulation technique to treat neurological disorders, including pain, traumatic brain injury (TBI), epilepsy, Parkinson s disease, Alzheimer s disease and more.
Given the increasing use of brain stimulation in human brain study and treatment of neurological diseases, this research can make a big impact on physicians and their patients.
Xiaoming Jin, PhD, associate professor of anatomy, cell biology and physiology
When someone experiences a brain injury, nerve injury, or neurodegeneration, such as in epilepsy and TBI, there is damage to the brain which can lead to loss and damage of nerve or neurons and development of hyperexcitability that underlies some neurological disorders such as neuropathic pain and epilepsy.
IU researchers pioneering noninvasive technique for neurological conditions eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
RespireRx Pharmaceuticals Inc. Provides Update on Its Development Programs
RespireRX Pharmaceuticals Inc.April 22, 2021 GMT
Glen Rock, N.J., April 22, 2021 (GLOBE NEWSWIRE) RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to provide an update on its therapeutic drug development programs.
EndeavourRx
Scientists associated with the Company have been invited by the prestigious journal,
Pharmacology and Therapeutics, to publish a review article describing the preclinical properties of its lead GABAkine compound, KRM-II-81, and its potential clinical therapeutic applications. The multidisciplinary team of authors have been led by Dr. James M. Cook6,7, Distinguished Professor, University of Wisc